Topotecan
- Generic Name
- Topotecan
- Brand Names
- Hycamtin, Potactasol, Topotecan Hospira
- Drug Type
- Small Molecule
- Chemical Formula
- C23H23N3O5
- CAS Number
- 123948-87-8
- Unique Ingredient Identifier
- 7M7YKX2N15
- Background
An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I.
- Indication
用于小细胞肺癌（SCLC）和一线治疗失败的晚期转移性卵巢癌。
- Associated Conditions
- Acute Myeloid Leukemia, Ewing's Sarcoma, Refractory Neuroblastoma, Metastatic Rhabdomyosarcoma, Recurrent Stage IVB Cervical Cancer, Refractory CNS lymphoma, Refractory CNS malignancy, Refractory, metastatic Ovarian cancer, Relapsed Platinum Sensitive Small Cell Lung Cancer (SCLC)
- Associated Therapies
- -
Trilaciclib (G1T28) in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2015-08-03
- Last Posted Date
- 2022-06-09
- Lead Sponsor
- G1 Therapeutics, Inc.
- Target Recruit Count
- 123
- Registration Number
- NCT02514447
- Locations
- 🇺🇸
Genesis Cancer Center, Hot Springs, Arkansas, United States
🇺🇸Highlands Oncology Group, Rogers, Arkansas, United States
🇺🇸Greenville Health System, Greenville, South Carolina, United States
Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer
- Conditions
- Fallopian Tube Clear Cell AdenocarcinomaFallopian Tube Endometrioid AdenocarcinomaFallopian Tube Serous AdenocarcinomaFallopian Tube Transitional Cell CarcinomaFallopian Tube Undifferentiated CarcinomaOvarian Clear Cell AdenocarcinomaOvarian Endometrioid AdenocarcinomaOvarian Seromucinous CarcinomaOvarian Serous AdenocarcinomaOvarian Transitional Cell Carcinoma
- Interventions
- First Posted Date
- 2015-07-20
- Last Posted Date
- 2024-07-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 587
- Registration Number
- NCT02502266
- Locations
- 🇺🇸
West Penn Hospital, Pittsburgh, Pennsylvania, United States
🇺🇸Pacific Gynecology Specialists, Seattle, Washington, United States
🇺🇸Women's Cancer Center of Seattle, Seattle, Washington, United States
Topotecan in Glioma Undergoing A Clinically-Indicated Surgical Resection
- Conditions
- Interventions
- First Posted Date
- 2015-07-16
- Last Posted Date
- 2019-03-01
- Lead Sponsor
- Michael Vogelbaum, MD, PhD
- Target Recruit Count
- 9
- Registration Number
- NCT02500459
- Locations
- 🇺🇸
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers
- Conditions
- Interventions
- First Posted Date
- 2015-07-01
- Last Posted Date
- 2024-03-05
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 62
- Registration Number
- NCT02487095
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Effectiveness Study of Nivolumab Compared to Chemotherapy in Patients With Relapsed Small-cell Lung Cancer
- First Posted Date
- 2015-06-25
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 569
- Registration Number
- NCT02481830
- Locations
- 🇺🇸
Local Institution - 0024, New Haven, Connecticut, United States
🇺🇸Local Institution - 0173, Johnson City, New York, United States
🇧🇷Local Institution - 0093, Barretos, Sao Paulo, Brazil
Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2015-04-20
- Last Posted Date
- 2020-04-03
- Lead Sponsor
- PharmaMar
- Target Recruit Count
- 442
- Registration Number
- NCT02421588
- Locations
- 🇺🇸
1120, Los Angeles, California, United States
🇺🇸1124, Scarborough, Maine, United States
🇺🇸1118, Dayton, Ohio, United States
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
- Conditions
- Advanced Malignant Solid NeoplasmClinical Stage III Cutaneous Melanoma AJCC V8Clinical Stage IV Cutaneous Melanoma AJCC V8Fallopian Tube CarcinomaMetastatic Lung Non-Small Cell CarcinomaMetastatic Malignant Solid NeoplasmMetastatic MelanomaMetastatic Renal Cell CarcinomaOvarian CarcinomaPathologic Stage III Cutaneous Melanoma AJCC V8
- Interventions
- Drug: CarboplatinDrug: EribulinDrug: FluorouracilDrug: PaclitaxelDrug: CyclophosphamideDrug: CapecitabineBiological: PembrolizumabDrug: OlaparibBiological: NivolumabBiological: IpilimumabDrug: SelinexorDrug: DoxorubicinDrug: TopotecanDrug: PemetrexedDrug: Irinotecan HydrochlorideDrug: OxaliplatinDrug: Leucovorin Calcium
- First Posted Date
- 2015-04-17
- Last Posted Date
- 2024-05-21
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 221
- Registration Number
- NCT02419495
- Locations
- 🇺🇸
MD Anderson in The Woodlands, Conroe, Texas, United States
🇺🇸M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸MD Anderson West Houston, Houston, Texas, United States
Simvastatin With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS Tumors
- First Posted Date
- 2015-03-18
- Last Posted Date
- 2020-04-03
- Lead Sponsor
- Emory University
- Target Recruit Count
- 13
- Registration Number
- NCT02390843
- Locations
- 🇺🇸
Children's Healthcare of Atlanta/Emory University, Atlanta, Georgia, United States
A Study of SGT-53 in Children With Refractory or Recurrent Solid Tumors
- First Posted Date
- 2015-02-03
- Last Posted Date
- 2022-02-08
- Lead Sponsor
- SynerGene Therapeutics, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT02354547
- Locations
- 🇺🇸
Texas Children's Hospital, Houston, Texas, United States
Phase II Study of Pazopanib and Topotecan in Cervical Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-01-28
- Last Posted Date
- 2016-08-16
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT02348398
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.